New study tracks long-term safety of DMD drug vamorolone in boys
Disease control
Recruiting now
This study follows 250 boys (ages 2 and older) with Duchenne muscular dystrophy who are taking vamorolone (AGAMREE). Researchers will monitor side effects, growth, bone health, heart function, and quality of life over time. The goal is to better understand the long-term safety an…
Sponsor: Catalyst Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC